Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

Journal of Medicinal Chemistry

Volumn 46, Issue 9, 2003, Pages 1627-1635

  Seefeld, Mark A ^a   Miller, William H ^a   Newlander, Kenneth A ^a   Burgess, Walter J ^a   DeWolf Jr , Walter E ^a   Elkins, Patricia A ^a   Head, Martha S ^a   Jakas, Dalia R ^a   Janson, Cheryl A ^a   Keller, Paul M ^a   Manley, Peter J ^a,b   Moore, Terrance D ^a   Payne, David J ^a   Pearson, Stewart ^a   Polizzi, Brian J ^a   Qiu, Xiayang ^a,c   Rittenhouse, Stephen F ^a   Uzinskas, Irene N ^a   Wallis, Nicola G ^a,d   Huffman, William F ^a  

^a GLAXOSMITHKLINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

^d ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL CARRIER PROTEIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE; FLAVOPROTEIN; INDOLE; INDOLENAPHTHYRIDINONE; NAPHTHYRIDINE DERIVATIVE; OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; PROTEIN FABI; PROTEIN FABK; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; CATALYSIS; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; FATTY ACID SYNTHESIS; IN VIVO STUDY; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; X RAY CRYSTALLOGRAPHY;

ABSCESS; ACRYLAMIDES; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENTEROCOCCUS FAECALIS; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; HAEMOPHILUS INFLUENZAE; INDOLES; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; NAPHTHYRIDINES; OXIDOREDUCTASES; RATS; STAPHYLOCOCCUS AUREUS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRICLOSAN;

EID: 0037464456     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0204035     Document Type: Article

References (43)

1. Bax, R.; Mullan, N.; Verhoef, J. The millennium bugs - the need for and development of new antibacterials. Int. J. Antimicrob. Agents 2000, 16, 51-59.
2. Setti, E. L.; Quattrocchio, L.; Micetich, R. G. Current approaches to overcome bacterial resistance. Drugs Future 1997, 22, 271-284.
3. Chu, D. T. W.; Plattner, J. J.; Katz, L. New directions in antibacterial research. J. Med. Chem. 1996, 39, 3853-3874.
4. Pearson, H. 'Superbug' hurdles key drug barrier. Nature 2002, 418, 469.
5. Payne, D. J.; Warren, P. V.; Holmes, D. J.; Ji, Y. D.; Lonsdale, J. T. Bacterial fatty acid biosynthesis: a genomics driven target for antibacterial drug discovery. Drug Discovery Today 2001, 6, 537-544.
6. Heath, R. J.; White, S. W.; Rock, C. O. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 2001, 40, 467-497.
7. Campbell, J. W.; Cronan, J. E., Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 2001, 55, 305-332.
8. Heath, R. J.; Rock, C. O. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 1995, 270, 26538-26542.
9. Bergler, H.; Fuchsbichler, S.; Högenauer, G.; Turnowsky, F. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. Eur. J. Biochem. 1996, 242, 689-694.
10. Heath, R. J.; Li, J.; Roland, G. E.; Rock, C. O. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 2000, 275, 4654-4659.
11. Rozwarski, D. A.; Grant, G. A.; Barton, D. H. R.; Jacobs, W. R., Jr.; Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998, 279, 98-102.
12. Baldock, C.; Rafferty, J. B.; Sedelnikova, S. E.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Hawkes, T. R.; Rice, D. W. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 1996, 274, 2107-2110.
13. Baldock, C.; de Boer, G.-J.; Rafferty, J. B.; Stuitje, A. R.; Rice, D. W. Mechanism of action of diazaborines. Biochem. Pharm. 1998, 55, 1541-1550.
14. Levy, C. W.; Baldock, C.; Wallace, A. J.; Sedelnikova, S.; Viner, R. C.; Clough, J. M.; Stuitje, A. R.; Slabas, A. R.; Rice, D. W.; Rafferty, J. B. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase. J. Mol. Biol. 2001, 309, 171-180.
15. McMurry, L. M.; Oethinger, M.; Levy, S. B. Triclosan targets lipid synthesis. Nature 1998, 394, 531-532.
16. Heath, R. J.; Yu, Y.-T.; Shapiro, M. A.; Olson, E.; Rock, C. O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 1998, 273, 30316-30320.
17. Levy, C. W.; Roujeinikova, A.; Sedelnikova, S. Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Rice, D. W.; Rafferty, J. B. Molecular basis of triclosan activity. Nature 1999, 398, 383-384.
18. McMurry, L. M.; McDermott, P. F.; Levy, S. B. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother. 1999, 43, 711-713.
19. Heath, R. J.; Rock, C. O. A triclosan-resistant bacterial enzyme. Nature 2000, 406, 145-146.
20. Heath, R. J.; Su, N.; Murphy, C. K.; Rock, C. O. The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis. J. Biol. Chem. 2000, 275, 40128-40133.
21. Heerding, D. A.; Chan, G.; DeWolf, W. E., Jr.; Fosberry, A. P.; Janson, C. A.; Jaworski, D. D.; McManus, E.; Miller, W. H.; Moore, T. D.; Payne, D. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Smith, W.; Takata, D. T.; Vaidya, K. S.; Yuan, C. C. K.; Huffman, W. F. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett. 2001, 11, 2061-2065.
22. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; DeWolf, W. E., Jr.; Keller, P. M.; Qiu, X.; Janson, C. A.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Jaworski, D. D.; Slater-Radosti, C.; Huffman, W. F. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 2001, 11, 2241-2244.
23. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Heerding, D. A.; Yuan, C. C. K.; Head, M. S.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; Pearson, S. C.; Berry, V.; DeWolf, W. E., Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Huffman, W. F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 2002, 45, 3246-3256.
24. Heck, R. F. Palladium-catalyzed vinylation of organic halides. Org. Reactions 1982, 27, 345-390.
25. Murakami, Y.; Sunamoto, J.; Kinuwaki, S.; Honda, H. Synthesis of Organic Phosphates. III. Synthesis and Properties of 2-amino-3-pyridylmethyl and 2-chloro-3-pyridylmethyl Phosphates. Bull. Chem. Soc. Jpn. 1973, 46, 2187-2190.
26. James, P. N.; Snyder, H. R. Organic Syntheses; Rabjohn, Norman, Ed.; Wiley: New York, 1963; Collect. Vol. IV, pp 539-542.
27. i value could not be determined.
28. The E. coli FabI assay used crotonoyl-CoA, rather than the natural substrate crotonoyl-ACP. See the Experimental Section for details.
29. Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J.; Chen, E.; DeWolf, W. E., Jr.; Fosberry, A. P.; Greenwood, R.; Head, M. S.; Heerding, D. A.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.; Vaidya, K.; Wallis, N. G.; Winram, S. B.; Yuan, C. C. K.; Huffman, W. F. Discovery of a novel and potent class of FabI directed antibacterial agents. Antimicrob. Agents Chemother. 2002, 46, 3118-3124.
30. Heath, R. J.; Rubin, J. R.; Holland, D. R.; Zhang, E.; Snow, M. E.; Rock, C. O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 1999, 274, 11110-11114.
31. Ward, W. H. J.; Holdgate, G. A.; Rowsell, S.; McLean, E. G.; Pauptit, R. A.; Clayton, E.; Nichols, W. W.; Colls, J. G.; Minshull, C. A.; Jude, D. A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N. J.; Britton, C. J.; Taylor, I. W. F. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 1999, 38, 12514-12525.
32. Marcinkeviciene, J.; Jiang, W.; Kopcho, L. M.; Locke, G.; Luo, Y.; Copeland, R. A. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene. Arch. Biochem. Biophys. 2001, 390, 101-108.
33. Fan, F.; Yan, K.; Wallis, N. G.; Reed, S.; Moore, T. D.; Rittenhouse, S. F.; DeWolf, W. E., Jr.; Huang, J.; McDevitt, D.; Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Jakas, D. R.; Head, M. S.; Payne, D. J. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 2002, 46, 3343-3347.
34. Suller, M. T. E.; Russell, A. D. Triclosan and antibiotic resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 2000, 46, 11-18.
35. Liu, B.; Wang, Y.; Fillgrove, K. L.; Anderson, V. E. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother. Pharmacol. 2002, 49, 187-193.
36. Mechanistic studies with 29 and S. aureus FabI showed mixed inhibition versus its cosubstrate NADPH and displayed inhibition parameters consistent with a preference for binding to the cofactor-bound form of the enzyme; Walter E. DeWolf, unpublished results.
37. Qiu, X.; Janson, C. A.; Court, R. I.; Smyth, M. G.; Payne, D. J.; Abdel-Meguid, S. S. Molecular basis for triclosan activity involves a flipping loop in the active site. Prot. Sci. 1999, 8, 2529-2532.
38. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods in Enzymology; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press: New York, 1997; Volume 276: Macromolecular Crystallography, part A, pp 307-326.
39. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR System: A new software suite for macromolecular structure determination. Acta Crystallogr. 1998, D54, 905-921.
40. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Cryst. 1991, A47, 110-119.
41. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
42. DeLano, W. L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA.
43. Koradi, R.; Billeter, M.; Wüttrich, K. MOLMOL: A program for display and analysis of macromolecular structures. J. Mol. Graphics 1996, 14, 51-55.